BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32816155)

  • 1. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
    Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
    Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
    Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
    Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
    Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab.
    Kamiimabeppu D; Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Yoshino K; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Oncol Lett; 2021 Nov; 22(5):783. PubMed ID: 34594424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of KRAS
    Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
    ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
    Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
    Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
    Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
    Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
    Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
    ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
    Yoshino T; Cleary JM; Van Cutsem E; Mayer RJ; Ohtsu A; Shinozaki E; Falcone A; Yamazaki K; Nishina T; Garcia-Carbonero R; Komatsu Y; Baba H; Argilés G; Tsuji A; Sobrero A; Yamaguchi K; Peeters M; Muro K; Zaniboni A; Sugimoto N; Shimada Y; Tsuji Y; Hochster HS; Moriwaki T; Tran B; Esaki T; Hamada C; Tanase T; Benedetti F; Makris L; Yamashita F; Lenz HJ
    Ann Oncol; 2020 Jan; 31(1):88-95. PubMed ID: 31912801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
    Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
    Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment.
    Fujimoto Y; Oki E; Qiu S; Nakanishi R; Makiyama A; Miyamoto Y; Kotaka M; Shimokawa M; Ando K; Kimura Y; Kitao H; Maehara Y; Mori M
    Cancer Sci; 2021 Jun; 112(6):2436-2441. PubMed ID: 33780084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
    Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
    ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
    Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
    Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.